Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Hemogenyx Pharmaceuticals plc has officially changed its registered office address to 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, effective immediately. This relocation aims to enhance operational efficiency and accessibility. Hemogenyx continues to focus on developing innovative treatments for blood diseases, with its corporate governance structure remaining intact. The announcement reflects the company’s commitment to maintaining a professional presence in a key financial district in London.
Hemogenyx Pharmaceuticals has reported that all resolutions were passed at its Annual General Meeting on June 30, 2022. Key resolutions included the adoption of the 2021 Annual Report, approval of the Directors' Remuneration Policy, and reappointment of the Company’s auditor. Notably, the resolution for the Directors' Remuneration Policy had 84.7% votes in favor, while the Employee Incentive Plan garnered 97.9% approval. The total issued share capital as of June 28, 2022, was 979,749,321 shares. Full voting details are available via the National Storage Mechanism.
Hemogenyx Pharmaceuticals plc has announced a live investor webinar hosted by CEO Dr. Vladislav Sandler on July 6, 2022, at 16:00 BST. The session will provide an overview of the company's activities and future directions, along with a Q&A segment. Interested parties can register here. Hemogenyx focuses on developing treatments for blood and autoimmune diseases, aiming to enhance the accessibility of bone marrow transplantation for patients with severe conditions. The firm is based in London and operates subsidiaries in New York City.
Hemogenyx Pharmaceuticals has posted its Annual Report and Accounts for the year ending December 31, 2021, alongside the Notice of the Annual General Meeting (AGM) to shareholders. The AGM is scheduled for June 30, 2022, at 2:00 PM BST in London. Key documents, including the 2021 Equity Incentive Plan, are accessible on the company's website. Shareholders can find further details through provided contact information.
Hemogenyx Pharmaceuticals announces that Andrew Wright, the Financial Controller and Company Secretary, purchased 1,284,889 ordinary shares at a price of 1.44p each. Post-transaction, Wright holds a total of 4,000,000 shares, representing approximately 0.41% of the company's issued capital. This acquisition signals confidence in the company's future performance, with the transaction value totaling £18,502.40. The purchase occurred on May 27, 2022, on the London Stock Exchange.
Hemogenyx Pharmaceuticals plc has announced its participation in the Immuno-Oncology Summit Europe 2022, taking place from May 23-25, 2022, where Dr. Vladislav Sandler will present on anti-FLT3 CAR-T and bispecific antibody therapies for treating acute myeloid leukemia. This presentation aims to showcase the company’s product candidates, including CDX bispecific antibody and HEMO-CAR-T, highlighting their potential benefits for patients. The participation emphasizes the company's position in the biopharmaceutical sector and aims to enhance visibility among industry leaders.
Summary not available.
Hemogenyx Pharmaceuticals has announced that the FDA has deferred its pre-Investigational New Drug meeting for its lead product candidate, HEMO-CAR-T, until May 2022. This change is due to the FDA prioritizing COVID-19 related work, but the company emphasizes that this will not delay HEMO-CAR-T's development or its IND filing. Additionally, progress continues positively on the CDX bispecific antibody for acute myeloid leukaemia and the CBR platform technology for viral diseases. The CEO reassures that the IND application remains on track despite the changes.
Hemogenyx Pharmaceuticals has formed a partnership with Selexis SA to enhance the development of its CDX bispecific antibody targeting acute myeloid leukemia (AML). This collaboration allows Hemogenyx to utilize Selexis' SUREtechnology Platform, streamlining the process of creating high-performance mammalian cell lines for clinical trials. The CDX bispecific antibody is aimed at offering an innovative therapy for AML patients, potentially increasing treatment efficacy and survival rates. The agreement marks a significant step towards advancing Hemogenyx's clinical initiatives.
Hemogenyx Pharmaceuticals announces its participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. CEO Dr. Vladislav Sandler will present the company's progress and product candidates via a virtual platform. The conference aims to enhance the company's visibility and inform investors about its advancements in developing therapies for blood diseases. Hemogenyx focuses on innovative treatments, particularly bone marrow transplantation, to address life-threatening conditions such as leukemia and autoimmune diseases.